Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 10;320(2):200-202.
doi: 10.1001/jama.2018.7999.

Testosterone Prescribing in the United States, 2002-2016

Jacques Baillargeon  1 , Yong-Fang Kuo  1 , Jordan R Westra  1 , Randall J Urban  2 , James S Goodwin  2
Affiliations

Testosterone Prescribing in the United States, 2002-2016

Jacques Baillargeon et al. JAMA. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Total and New Testosterone Use, 2002–2016, among Men ≥ 30 Years of Age
Denominators were calculated for each calendar year. Each denominator included all men who were ≥ 30 years at the start of the calendar year with continuous benefits for the entire study year and prior year. Error bars represent 95% confidence intervals. Interrupted time series analysis with joinpoint regression was used to assess time related trends in testosterone use. The analysis allowed for a maximum of 5 joinpoints. Joinpoints are indicated by red arrows. For total testosterone use, joinpoints were located at 2007 (95% Cl: 2005–2010) and 2013 (95% Cl: 2012–2014). For new testosterone use, joinpoints were located at 2007 (95% Cl: 2004–2012) and 2012 (95% Cl: 2010–2014. The upper left panel presents new testosterone prescription rates by month, from January 2012 through December 2015. Denominators for monthly rates included all men ≥ 30 at the start of the month with continuous benefits for the entire month and the 12 previous months. The listed numbers indicate the following specific dates: 1. Article by Vigen et al. released online November 6, 2013; 2. Article by Finkle et al. released online January 29, 2014; 3. FDA safety communication on testosterone therapy, January 31, 2014; 4. FDA advisory committee meeting on possible cardiovascular risks associated with testosterone therapy, September 17, 2014; 5. FDA requires testosterone label change indicating possible increased risk of myocardial infarction and stroke, March 3, 2015.
Figure 2.
Figure 2.. Rates of New Testosterone Use by Calendar Year, Stratified by Age and Region
Regions were based on US census regions. NE = northeast; MW = Midwest; SO = south; WE = west. Error bars reflect the 95% confidence intervals. The denominators for any age category in any year ranged from 284,602 to 1,109,387. The denominators for any region category in any year ranged from 11,999 to 1,106,148.
See this image and copyright information in PMC

Comment in

References

    1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in Androgen Prescribing in the United States, 2001–2011. JAMA Intern Med 2013;173(15):1465–1466. - PMC - PubMed
    1. Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835–842. - PMC - PubMed
    1. Vigen R, O’Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–1836. - PubMed
    1. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;29:e0085805. - PMC - PubMed
    1. Jasuja GK, Bhasin S, Rose AJ. Patterns of testosterone prescription overuse. Curr Opin Endocrinol Diabetes Obes. 2017;24(3):240–245. - PubMed

Publication types